About the Company
We do not have any company description for Kymera Therapeutics, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Kymera Therapeutics, Inc.
Analysts Are Updating Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Estimates After Its Second-Quarter Results
NasdaqGM:KYMR 1 Year Share Price vs Fair Value Explore Kymera Therapeutics's Fair Values from the Community and ...
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...
Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ...
Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.58 per share a year ago. These ...
Kymera Therapeutics Announces Closing of Upsized $225 Million Public ...
WATERTOWN, Mass., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using ...
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings ... - Nasdaq
Wall Street expects a year-over-year decline in earnings on higher revenues when Kymera Therapeutics, Inc. (KYMR) reports results for the quarter ended March 2024. While this widely-known ...
Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday
We recently published a list of These 10 Stocks Blew Past Expectations. In this article, we are going to take a look at where Kymera Therapeutics, Inc. (NASDAQ:KYMR) stands against other ...
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.06 Consensus PT ...
Blue Trust Inc. boosted its stake in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after acquiring an ...
Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 ... - Nasdaq
The market expects Kymera Therapeutics, Inc. (KYMR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2023. This widely ...
Kymera Therapeutics Announces Proposed Public Offering
WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader ...
Similar Companies
Loading the latest forecasts...